In a retrospective single center study, we examined the outcome of induced GVHD in leukemia patients relapsing after allogeneic BMT. Thirty-three adult patients with leukemia (15 AML, 3 ALL, and 15 CML) persisting or relapsing 1-36 months (median, 6) after allogeneic BMT underwent various immune manipulations and consequently developed acute and/or chronic GVHD at our center. Immunotherapies to elicit GVHD comprised chemotherapy followed by PBSC (n = 18), non-myeloablative transplant (n = 2), PBL followed by IFN-␣ (n = 5), PBL alone (n = 3), abrupt cessation of CsA (n = 3), and CsA withdrawal combined with IFN-␣ (n = 2). Twenty-four (72.7%) patients obtained a remission including complete hematological or cytogenetic remission, respectively, for acute leukemias or CML. Overall survival of patients, estimated at 3 years using the Kaplan-Meier method, was 33.9% (95% CI, 20-52%). Twelve patients including two patients with ALL remain in complete hematological (n = 5) or cytogenetic remission (n = 7) 3-93 months (median 12) after achieving remission. Twelve (63.2%) of 19 dead patients died due to treatment-related toxicities; five patients from acute GVHD, three from GVHD followed by infections and four from infections. By multivariate Cox analysis, only chronic GVHD resulted in a higher probability of disease-free survival (P = 0.026). Eight patients who had both acute GVHD р grade I and chronic GVHD are all alive without leukemia. We conclude that acute GVHD is associated with considerable toxicity while chronic GVHD plays a role in retaining remission in leukemia relapsing after allogeneic BMT. Bone Marrow Transplantation (2001) Leukemic relapse after allogeneic BMT is an important cause of treatment failure. The risk of leukemic relapse varies from 20% to 60% depending on the diagnosis and phase of the disease. 
Leukemic relapse after allogeneic BMT is an important cause of treatment failure. The risk of leukemic relapse varies from 20% to 60% depending on the diagnosis and phase of the disease. 1 Treatment options for acute leukemia relapsing after allogeneic BMT include conventional chemotherapy with 2, 3 or without 4, 5 PBSC infusion or a second transplant. 6, 7 Therapy with IFN-␣ results in cytogenetic remission in approximately 10-30% patients with CML. 8 In an attempt to induce a GVL effect, donor leukocyte infusion (DLI) from the original donor was initiated by Slavin et al, 9 for relapsed patients with ALL and has been used for relapsed patients with acute and chronic leukemia. 9, 10 Remission of leukemia persisting or relapsing after allogeneic BMT has been reported to follow a tapering or abrupt discontinuation of immunosuppression. 11 Treatment methods using immunologic GVL effects have been exploited successfully to treat leukemia relapsing after allogeneic transplant. 9, [12] [13] [14] [15] GVL effects are closely associated with the presence of GVHD 16 , which results in either a higher probability of survival or remains a major limitation of relapse treatment due to its excessive toxicity. GVHD remains a significant risk factor even in relapsed patients. 17 Ultimately, the ability to harness GVL, without inducing excessive toxicity from GVHD, will be a central challenge for treating relapsing leukemia patients.
In this report, we evaluated the probability of remaining in remission by examining GVL effects and toxicities in relapsing patients that had a clinically obvious GVHD after various immunotherapies, which included abrupt cessation of CsA, IFN-␣, donor leukocyte infusion with or without chemotherapy. In addition to these, the correlation between the type and severity of induced GVHD and GVL effects was also assessed.
Patients and methods

Patient characteristics and prior treatment
Between March 1992 and May 2000, 33 adult patients with acute (n = 18) or chronic (n = 15) leukemia, relapsing after allogeneic BMT underwent various immune manipulations in an attempt to induce GVL and, consequently, developed acute and/or chronic GVHD at the Catholic Hemopoietic Stem Cell Transplantation Center. Their characteristics are summarized in Table 1 , and details of the diagnosis in Table 2 . All CML patients were positive for Ph chromosome. The median age was 30 years (range 14-44); 26 were male, and seven female. All patients except one had under- ). 20 GVHD prophylaxis after BMT consisted of CsA and a short course of MTX. 21 
Relapse
In acute leukemia, relapse was defined as either leukemic blasts accounting for more than 5% of nucleated cells in bone marrow or extramedullary leukemic cell infiltrations regardless of numbers of blasts in marrow. In CML, hematological relapse was defined as peripheral blood leukocytosis with a predominance of myelocytes and neutrophils in the differential count. This was accompanied by a hypercellular marrow and Ph chromosome positivity on cytogenetic analysis. Cytogenetic relapse of CML was considered to be present if one or more Ph + metaphases were detected without evidence of hematological relapse. 14 According to tumor burden in the bone marrow on relapse, patients were classified into early disease (n = 12, normal marrow with chloroma, cytogenetic relapse CML, chronic phase CML and accelerated phase CML) and advanced disease (n = 21, acute leukemia and blastic phase CML).
Treatment for relapsing leukemia by immune manipulation
As a first step, all relapsing patients discontinued CsA. In relapsed patients with early disease, PBL and/or IFN-␣ were given without any prior chemotherapy only when GVHD had not occurred. Chloroma was treated by radiation therapy. Chemotherapy was not administered to chronic phase CML patients except hydroxyurea, as required, to control counts prior to immune manipulation. Chemotherapy prior to PBSC was administrated to patients with advanced disease on relapse. Patients receiving standard-dose chemotherapy, which was non-myeloablative, were included in this study and those conditioned with myeloablative doses of chemotherapy or chemoradiotherapy for a second allogeneic transplant procedure were excluded.
One relapsed ALL patient received PBL without chemotherapy due to the patient refusing chemotherapy, and one CML patient with granulocytic sarcoma in the central nervous system received chemotherapy followed by PBSC infusion because of progressive neurological symptoms. One blastic phase CML patient who discontinued CsA and developed acute GVHD уII could not receive chemotherapy. DLI: Donor leukocytes were obtained from PBSC or PBL. PBSC were mobilized from the original bone marrow donor with 10 g/kg G-CSF s.c. on 4 consecutive days. 24 Aphereses were performed on the fifth day, and depending on the harvested cell number also on day 6. We planned to obtain 2 ϫ 10 6 CD34 + cells/kg of recipient weight, and any additional collections were cryopreserved for possible future use. PBL were collected by a single apheresis in the basal state. Patients were intended to receive escalating doses of CD3 + cells starting from 5 ϫ 10 7 /kg up to 2 ϫ 10 8 /kg every 21 days. One patient received PBL in other hospital with a dose of 2.7 ϫ 10 7 /kg.
Chemotherapy
IFN-␣:
Interferon was usually started at 3 million units per 2 days s.c., and this was then increased as tolerated symptomatically to 3-5 million units three to seven times a week until the development of GVHD.
Assessment and treatment of GVHD
Acute GVHD was graded on a four-point scale (I indicated mild disease, and IV severe disease) [25] [26] [27] and chronic GVHD was classified as limited or extensive, as previously described.
28,29 GVHD was designated acute or chronic depending on the clinical picture rather than on the basis of a 100-day period following immunotherapy. 15 Skin, rectum, or liver biopsies were performed when indicated to confirm GVHD.
All patients except two that underwent the non-myeloablative transplant did not receive any GVHD prophylaxis. If the underlying malignancy was in remission, acute GVHD was treated when it was уgrade II. However, immunosuppressants were promptly discontinued on improvement. In patients with incomplete remission, acute GVHD was treated when it was life-threatening (grade III with complicating medical problems or grade IV). In chronic GVHD, immunosuppressants were administered when it became extensive.
Definition of response
In acute leukemias, response was considered to be complete hematological remission (CHR). CHR was defined as an Bone Marrow Transplantation ANC above 1 ϫ 10 9 /l in the peripheral blood with the bone marrow showing less than 5% of blast cells for at least 4 weeks and the disappearance of all measurable disease. Normalization of blood counts was not a requirement for defining remissions because pancytopenia related to GVHD or DLI was anticipated in a proportion of the patients. 15 In CML, response was decided by cytogenetic remission, 14 which was documented either if no Ph + metaphases were detected on conventional cytogenetic analysis of at least 20 metaphases or when the numbers of bcr/abl fusion signals were below the cutoff value on interphase fluorescence in situ hybridization (FISH).
Statistical analysis
Results quoted were current as of 31 July 2000. The probabilities of disease-free survival (DFS) and overall survival after relapse were calculated using the Kaplan-Meier (KM) product limit estimator. Cumulative incidence curves of DFS are presented as estimates of the probability of certain events (such as relapse, persistent leukemia, or death) and compared by the log-rank test from SPSS for Windows (release 9.9.0). Multivariate analysis using Cox regression was performed to examine the factors effecting DFS. Fisher exact test of Crosstabs analysis in SPSS was used to compare GVHD incidence in terms of transplant characteristics.
Results
Methods for Induction of GVHD
The methods leading to GVHD induction are shown in Table 3 . GVHD was induced in five (15.2%) patients without re-infusion of donor cells. Two patients with cytogenetic relapse CML and one patient with blastic phase CML developed GVHD after CsA withdrawal alone. Twenty-eight (85%) patients received donor cells. Donor leukocytes, administered to 28 relapsing patients, were obtained using either PBSC (n = 20) or PBL (n = 8). PBSC followed the chemotherapy 2,3 (n = 18) or non-myeloablative conditioning regimen 22, 23 (n = 2), and contained a median dose of 9.1 (range 2.5-14. /kg (range 27-350). None of the patients had active GVHD at the time of immune manipulation and cell infusions were Table 3 Actual treatments given our patients Twenty-six (78.9%) of 33 patients had acute GVHD following immunotherapy; three, 11, three and nine patients had overall grades I, II, III, and IV, respectively. Eighteen (64.3%) of 28 evaluable patients developed chronic GVHD; acute followed by extensive chronic (n = 3), limited chronic (n = 4) and de novo chronic (n = 11, six extensive).
Five of 18 patients who had acute and/or chronic GVHD prior to relapse had acute GVHD у grade III after immunotherapy, compared with seven of 15 patients who did not have the GVHD (P = 0.431, Fisher's exact test). The incidence of chronic GVHD after immunotherapy did not differ according to the GVHD prior to relapse (P = 1.0, Fisher's exact test). The administration of chemotherapy prior to DLI was not associated with the occurrence of more severe acute GVHD (grade I-II vs III-IV, P = 0.391, Fisher's exact test) or chronic GVHD (P = 0.254, Fisher's exact test). CD3
+ lymphocytes in donor leukocytes did not influence the severity of acute GVHD or the occurrence of chronic GVHD (Ͻ257.5 ϫ 10 6 /kg vs у257.5ϫ10 6 /kg, P = 1.0 and 0.662, respectively, Fisher's exact test).
Toxicity
Eight (24.2%) patients died of GVHD; acute GVHD (n = 5), acute GVHD + pneumonia (n = 1), pneumonia combined with both acute and chronic GVHD (n = 1), and chronic GVHD + pneumococcal sepsis (n = 1). Other therapy-related deaths were idiopathic pneumonitis syndrome (n = 1), fungal pneumonia (n = 1), pneumococcal sepsis (n = 1), and pulmonary empyema (n = 1). One patient who received PBL, developed prolonged pancytopenia due to marrow aplasia but recovered after infusion of G-CSFmobilized PBSC.
Remission
As can be seen in Table 2 , 24 (72.7%) patients obtained a remission including CHR or cytogenetic remission following immunotherapy. Relapse after BMT was successfully reversed in 11 of 15 with CML, three of three with ALL, and 10 of 15 with AML. Induced GVHD resulted in remission in eight of 10 patients who relapsed with early CML; both patients with cytogenetic relapse of CML and six of eight with hematological relapse in the chronic phase of CML responded to GVHD by achieving and maintaining cytogenetic remission. Cytogenetic relapses of CML patients were reversed on withdrawal of immunosuppression and with the onset of GVHD. Three ALL patients (100%) achieved remission after GVHD. A Ph-positive patient remains in remission after 15 months and a Ph-negative patient for 10 months. The patient who received PBL without antecedent chemotherapy died of grade IV acute GVHD in remission. Ten (66.7%) of 15 patients with AML obtained a remission; only two (20%) of these remitted patients relapsed and five (50%) of them died of acute GVHD and its associated infections.
Among those responding, 12 patients remain in CHR (n = 5) or cytogenetic remission (n = 7) 3-93 months (median 12) after achieving remission. Nine (37.5%) of 24 patients with a remission died of treatment-related complications, which consisted of GVHD (n = 5) and infections (n = 4). Three patients, two AML and one CML, relapsed 2+, 6+, and 7+ months after achieving remission. One of the three relapsed patients is alive with disease.
Seven (21.2%) patients showed no remission in spite of the occurrence of GVHD. Among these non-responders, three of four AML patients and one of three CML were in advanced disease prior to transplant. Five of seven patients who did not obtain a remission died of progressive disease, one died from infection during chronic phase of CML and one is alive with disease. Two patients who received chemotherapy + PBSC died of acute GVHD within 2 months of starting immunotherapy, and their responses could not be evaluated. Five patients relapsed with extramedullary disease. Four of five patients with extramedullary leukemia died from disease progression (n = 2) or acute GVHD following immunotherapy (n = 2). One patient with extensive chronic GVHD showed complete regression, but was lost during follow-up.
Survival
Twelve (36.4%) of 33 patients were alive and two patients were lost in remission during follow-up. Overall survival of patients, estimated at 3 years using the Kaplan-Meier method, was 33.9% (95% CI: 20-52%) with a median follow up of 17 months (2-96) (Figure 1) . Nineteen (57.6%) patients died. Seven patients died of disease progression, and 12 patients died of treatment-related toxicities; five patients from acute GVHD, three from GVHD + infections, and four from infections.
Kaplan-Meier estimated DFS was compared according to the underlying disease (acute leukemias vs CML, 17.8% vs 45%, P = 0.096), disease status before BMT (minimal vs advanced, 39.0% vs 15.0%, P = 0.135), disease status at relapse (early vs advanced, 57.3% vs 14.8%, P = 0.009), interval from BMT to relapse (Ͻ6 months vs у6 month, 12.5% vs 54.6%, P = 0.051), prior chemotherapy (patients who received chemotherapy vs patients who did not, 14.7% vs 53.3%, P = 0.033), infused CD3 + lymphocyte count (Ͻ257.5 ϫ 10 6 /kg vs у257.5 ϫ 10 6 /kg, 29.2% vs 25.0%, P = 0.517), severity of acute GVHD (I-II vs III-IV, 19.2% vs 20.0%, P = 0.982), and chronic GVHD (presence vs absence, 60.8% vs 0%, P Ͻ 0.001). Patients with acute GVHD у grade II showed lower DFS than those that had mild acute GVHD (grade I) and those that did not (15.0% vs 64.8%, P = 0.013).
In multivariate Cox analysis, only chronic GVHD occurrence was associated with better DFS (P = 0.026) ( Table  4 ). Eight patients who had both acute GVHD рgrade I and chronic GVHD were all alive without leukemia.
Discussion
The antileukemic effect of GVHD is well known and the GVL effect elicited by GVHD has been used to treat leukemia relapse after allogeneic transplantation. [9] [10] [11] [12] [13] [14] [15] In the present report, the characteristics and outcome of GVHD following various immunotherapies for relapsing leukemia were retrospectively analyzed. CsA withdrawal 11 , IFN-␣ therapy, 8 DLI alone, 9,10 and chemotherapy followed by DLI were examined. 2, 3 Our major concerns were to what degree GVHD elicited by the immunotherapies had a role in sustaining extended remission and to what extent GVHD itself and its associated toxicities should be induced in relapsed leukemia patients.
Our patients, who had advanced disease on relapse, did not receive myeloablative conditioning and needed GVL effects to sustain long-term remission. Consequently, their therapeutic effect probably involved a direct pharmacological suppression of the leukemic clone, followed by a GVL effect initiated by donor-derived alloreactive lymphocytes. G-CSF-mobilized PBSC were infused after the chemotherapy cycle in an attempt to accelerate hematopoietic regeneration and to induce a GVL effect. 2, 3 Patients who had early disease on relapse, received PBL with or without IFN-␣. Five patients developed GVHD following CsA Table 4 Variables affecting the probability of disease-free survival by multivariate analysis. 15 reported that in relapsing leukemia patients, clinically evident GVHD, especially chronic GVHD, resulted in a high probability of survival. In our analysis, DFS, which was defined as a duration of remaining in remission was considered to be dependent on the GVL effect elicited by GVHD. By multivariate analysis, chronic GVHD occurrence and no or mild acute GVHD were important factors for predicting better DFS (P = 0.026, 0.097, respectively). Severe acute GVHD involved high therapy-related mortality and nine (37.5%) of 24 patients with a remission died of either acute GVHD or infections. Acute GVHD was inversely associated with DFS and, to the contrary, chronic GVHD was helpful in maintaining long-term remission. All eight patients having both chronic GVHD and mild acute GVHD were alive in remission at the time of writing.
Durable complete remission can be achieved at the molecular level for the majority (more than 70%) of patients with CML, when treated at early relapse. 30, 31 Results are less favorable for patients with relapse of acute leukemia or advanced CML, although useful responses have been reported. 31, 32 In acute leukemia patients who relapse after allogeneic BMT, the chemotherapy results in a CR rate of approximately 35-50%. However, most patients finally relapse on chemotherapy without any immunotherapy and die of uncontrolled leukemia. 1 In our patients who had clinical evidence of GVHD, DFS of patients in the early disease phase on relapse was also superior to those in advanced disease who had received antecedent chemotherapy (P = 0.009). Figure 2 shows that patients in the chronic phase or cytogenetic relapse CML at the time of immunotherapy, have a better DFS rate than those who are in blastic crisis CML or acute leukemia (P = 0.016). However, we believe that the induced GVHD might have, to some degree, a remission-sustaining effect on acute leuke- mia. Patients with AML had a probability of 11.54% of achieving and remaining in hematological remission 3 years after relapse post BMT. Half of the patients with a remission after various immunotherapies died from GVHD. It seemed important to successfully treat relapsing AML patients without the development of potentially fatal toxic GVHD. With regard to ALL, our result shows that induced GVHD produced an effect on GVL. The efficacy of DLI in ALL was subject to debate in previous publications. Results in the EBMT study 33 showed complete remissions were also induced in some patients with AML, but ALL did not respond to adoptive immunotherapy with DLI. Remissions after chemotherapy were not durable in recurrent ALL. In retrospective analysis 34 from 25 North American BMT units, remissions were observed less frequently in patients with acute leukemia. In these reports, 33, 34 GVHD, which was closely associated with disease response, occurred in approximately 60% of the assessable patients and therefore the GVHD-associated antileukemic effect seemed to be less prominent. On the contrary, durable remissions could be induced in relapsing ALL patients who received PBL and subsequently developed GVHD. 9 In that report, 9 the relapsing patients who did not develop GVHD after allogeneic cell therapy could not obtain a remission. All our patients had GVHD after various immune manipulations. The number of cells infused in the present study appeared higher than those of the EBMT 33 or North American Group. 34 Among leukemia phenotypes, HLA-class II antigens, which may serve as targets for GVHD and GVL, were highest in B lineage ALL cells. 35 It is thus plausible that the antileukemia effect of GVHD might occur preferentially in the HLA class II-bearing B cell ALL. All phenotypes were B cells in our ALL patients.
One AML patient who had limited chronic GVHD following immunotherapy obtained CHR but, after 7 months, developed isolated extramedullary relapses in an eyelid and the right breast while in full hematological remission, and this was followed by dissemination of blast cells into the bone marrow. One CML patient with granulocytic sarcoma in the central nervous system, remained free of disease after immunotherapy and radiation, but mass size re-increased despite extensive chronic GVHD. These cases suggest that immunologically privileged or extramedullary sites are inaccessible to the GVHD/GVL effect. 36 However, a nasopharyngeal chloroma in one AML patient completely regressed in association with extensive GVHD, which occurred after CsA withdrawal followed by IFN-␣. Whether GVHD plays a role in inducing and maintaining remission for extramedullary relapse should be investigated.
The effector cells involved with GVHD and GVL are incompletely defined. Both CD4 + and CD8 + T cells participate in the initiation of GVHD; other cell populations, including NK cells, are subsequently recruited, and cytokines are likely mediators of tissue damage. [37] [38] [39] In human BMT recipients, both CD4
+ and CD8 + antileukemic T cell lines or clones have been described. 40, 41 In contrast to chemotherapy and radiation therapy, GVHD elicited by immunotherapy that operates by different mechanisms may destroy tumor cells despite their full resistance to all available anti-leukemic modalities. Induced GVHD sustained long-term remission in our relapsing patients who probably had resistance to chemotherapy and radiation therapy. However, therapeutic attempts are necessary to enhance antileukemic efficacy and lessen the toxicity related to GVHD. Infusion of lower cell doses or various T cell subsets, coadministration of cytokines such as IL-2, insertion into lymphocytes of a suicide gene, and other methods isolating donor cells with antileukemic selectivity might be required. We believe that toxicity may be improved by strict control and consequent treatment of acute GVHD уgrade II. In our patients, acute GVHD уgrade II led to poorer survival than grade 0-I (15.0% vs 64.8%, P = 0.013) but chronic GVHD played a role in sustaining a remission.
In summary, the results of this study show that GVHD elicited by various immunotherapies can induce an effective GVL reaction leading to remission in patients with relapsing leukemia including ALL. However, acute GVHD continues to be a major cause of mortality and its severity needs to be modulated. Continuing remission is favored by chronic GVHD occurring after immunotherapy.
